Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 3/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.53 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 10/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10937597 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL11770996 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL1104430 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL10933452 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL6242053 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL10934245 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL10934552 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL10937702 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL10935342 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 | |
| SCHEMBL6237192 | 1.00 | PLA2G1B (0.53) | PLA2G1BATG4BHSP90AA1PSMD14MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0756633-B1 | METHOD AND KITS FOR PROCESSING MYCOBACTERIA AND MYCOLIC ACID CONTAINING BACTERIA | INTEGRATED RES TECHNOLOGY LLC (US) | 2005-06-08 | — | — | EP | claimed |
| US-12528775-B2 | Oxygenated and amino- or ammonium-containing phosphonic acid derivatives and their medical use | GRI BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3597634-B1 | OXYGENATED AMMONIUM-CONTAINING SULFONIC ACIDS AND THEIR MEDICAL USE | GRI BIO INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230265052-A1 | OXYGENATED AND AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE | ALTIUM GROWTH FUND, LP | 2023-08-24 | — | — | US | disclosed |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | POVIVA CORP | 2023-03-30 | — | — | US | disclosed |
| EP-4117684-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF ANTIVIRAL AGENTS | Poviva Corp. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11453642-B2 | Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use | GRI BIO, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220192994-A1 | SOFTGEL FILL MATERIAL | BARLEAN'S ORGANIC OILS, LLC (US) | 2022-06-23 | — | — | US | disclosed |
| US-20220160731-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | POVIVA CORP | 2022-05-26 | — | — | US | disclosed |
| US-11311559-B2 | Compositions and methods for enhanced delivery of antiviral agents | Poviva Corp. (US) | 2022-04-26 | — | — | US | disclosed |
| US-4064076-A | ETHOXYLATED ALKYL SULFATE, TERTIARY AMINE OXIDE | COLGATE-PALMOLIVE (US) | 1977-12-20 | — | — | US | disclosed |
| US-4061586-A | LIQUID | COLGATE-PALMOLIVE COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061602-A | Conditioning shampoo composition containing a cationic derivative of a natural gum (such as guar) as the active conditioning ingredient | AMERICAN CYANAMID COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4049665-A | 1-OXO-2-PYRIDYL DISULFIDES; FOR USE IN SKIN CLEANSERS, SHAMPOOS, HAIR DRESSINGS, DISINFECTANTS, PRESERVATIVES | COLGATE-PALMOLIVE COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
| US-4048181-A | MICROBIOCIDES, ANTISEPTICS | COLGATE-PALMOLIVE COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4023978-A | Aerosol spray starch formulation | COLGATE-PALMOLIVE COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
| US-3979340-A | Olefin sulfonate detergent compositions | COLGATE-PALMOLIVE COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
| US-3974082-A | Bleaching compositions | COLGATE-PALMOLIVE COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
| US-3970596-A | Non-gelling alpha-olefin sulfonate liquid detergent | COLGATE-PALMOLIVE COMPANY (US) | 1976-07-20 | — | — | US | disclosed |
| US-3940482-A | ALIPHATIC POLYAMINE, SOLVENT, FUNGICIDE, BACTERICIDE | COLGATE-PALMOLIVE COMPANY (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220192994-A1 | SOFTGEL FILL MATERIAL | LIPA, MGLL, PNLIP | PLA2G1B 52/4885ATG4B 1965/4885HSP90AA1 373/4885 |
| US-11311559-B2 | Compositions and methods for enhanced delivery of antiviral agents | SARS1, ACE, ACE2 | PLA2G1B 752/4885ATG4B 286/4885HSP90AA1 2656/4885 |
| US-11453642-B2 | Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use | AADAT, ASS1, IL4I1 | PLA2G1B 1039/4885ATG4B 3749/4885HSP90AA1 2352/4885 |
| US-12528775-B2 | Oxygenated and amino- or ammonium-containing phosphonic acid derivatives and their medical use | OXGR1, OXER1, MALT1 | PLA2G1B 1261/4885ATG4B 4639/4885HSP90AA1 2905/4885 |
| US-20230265052-A1 | OXYGENATED AND AMINO- OR AMMONIUM-CONTAINING SULFONIC ACID, PHOSPHONIC ACID AND CARBOXYLIC ACID DERIVATIVES AND THEIR MEDICAL USE | ASS1, AADAT, ASPH | PLA2G1B 1101/4885ATG4B 3811/4885HSP90AA1 2385/4885 |
| US-20220160731-A1 | COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE AGENTS AND BILE SALTS | SLC10A2, ABCB11, SLC10A1 | PLA2G1B 303/4885ATG4B 1609/4885HSP90AA1 502/4885 |
| US-20230094827-A1 | NANOEMULSION COMPOSITIONS COMPRISING BIOLOGICALLY ACTIVE INGREDIENTS | PNLIP, LIPA, SGMS2 | PLA2G1B 42/4885ATG4B 237/4885HSP90AA1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.